Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Planned sale Director sold 1,666 shares at $18.37 ($30,604)
  2. 4 Open-market sale Director sold 2,750 shares at $17.29 ($47,548)
  3. 4 Open-market sale President and CEO sold 9,589 shares at $17.29 ($165,794)
  4. 4 Planned sale Chief Medical Officer sold 4,189 shares at an average $17.46 ($73,130)
  5. 4 Planned sale COFO and Secretary sold 22,844 shares at an average $17.62 ($402,420)
  6. 4 Option exercise COFO and Secretary acquired 50,000 shares (option exercise)
  7. 4 Planned sale Director sold 1,666 shares at $18.42 ($30,688)
  8. 4 Planned sale Chief Medical Officer sold 4,668 shares at $19.02 ($88,785)
  9. 4 Open-market sale President and CEO sold 7,818 shares at $19.78 ($154,640)
  10. 4 Open-market sale Chief Medical Officer sold 9,972 shares at $19.43 ($193,756)
  11. 4 Open-market sale Director sold 3,208 shares at $19.43 ($62,331)
  12. 4 Open-market sale COFO and Secretary sold 9,972 shares at $19.43 ($193,756)
  13. 4 Open-market sale President and CEO sold 17,483 shares at $19.43 ($339,695)
  14. 4 Grant or award COFO and Secretary acquired 53,720 shares (grant or award)
  15. 4 Grant or award Chief Medical Officer acquired 53,720 shares (grant or award)
  16. 4 Grant or award President and CEO acquired 89,520 shares (grant or award)
  17. 4 Planned sale Director sold 1,666 shares at $23.39 ($38,968)
  18. 4 Planned sale Director sold 1,666 shares at $19.13 ($31,871)
  19. 4 Planned sale Director sold 1,666 shares at $20.66 ($34,420)
  20. 4 Planned sale Director sold 1,666 shares at an average $23.62 ($39,348)

Page 5 of 22 · 436 filings